USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Athena Neurosciences Inc.
Address:
800f Gateway Blvd
S San Francisco, CA 94080
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $250,000.00 5
SBIR Phase II $799,064.00 2

Award List:

IDENTIFICATION OF ALZHEIMER'S-SPECIFIC TAU ALTERATIONS

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
Alzheimer's disease (ad) is a devastating illness currently affecting over 2.5 million people in the united states, withfinancial costs for diagnosis and long-term care exceeding $50 billion annually. the etiology of ad is unknown, but its two biochemical hallmarks are the presence of extracellular… More

IDENTIFICATION OF ALZHEIMER-SPECIFIC ANTIGENS IN CSF

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
The objective of this research is to define antigens in the cerebrospinal fluid (csf) that are specific to alzheimer's disease. ultimately, the potential results of this effort may be the development of a csf-based diagnostic immunoassayfor use both as a diagnostic marker and as a useful adjunct to… More

SYNTHESIS AND EVALUATIONOF AGENTS FOR BRAIN NEOPLASMS

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
The poor prognosis associated with brain neoplasms is a significant health problem in the united states. current chemotherapeutic approaches have been limited by the inability to achieve therapeutic concentrations in the brain. cyclophosphamide is unique among widely used chemotherapeutic agents in… More

IN VITRO MODEL OF THE BLOOD-BRAIN BARRIER

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

CHARACTERIZ. OF AMYLOID PRECURSOR FRAGMENTS IN PLASMA

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

IN VITRO MODEL OF THE BLOOD-BRAIN BARRIER

Award Year / Program / Phase:
1990 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Abstract:
The barrier to diffusion and transport of substances from the blood into the brain is denoted the blood-brain barrier. the blood-brain severely limits delivery to the brain of drugs that could be beneficial for treatment of central nervous systems (cns) diseases. current methods for testing drug… More

CHARACTERIZ. OF AMYLOID PRECURSOR FRAGMENTS IN PLASMA

Award Year / Program / Phase:
1990 / SBIR / Phase II
Award Amount:
$299,064.00
Agency:
HHS
Principal Investigator:
Abstract:
Alzheimer's disease is currently thought to affect as many as 1 to 3 million people in the united states alone. it hasrecently been found that the core a4 peptide of the senile person's plaque (one hallmark of the disease) is derived from a precursor protein 695 to 750 amino acids long. it is not… More